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| INTRODUC TI ON
Esophageal squamous cell carcinoma (ESCC) is a refractory digestive organ cancer that shows high morbidity in East Asia. It remains difficult to treat despite multidisciplinary therapy that includes tumor excision, chemotherapy and radiotherapy. 1 Hence, a new treatment strategy for ESCC is required. We recently reported that metformin, which is an oral biguanide for treating type 2 diabetes mellitus, exerts antitumor effects in ESCC by inhibiting nuclear translocation of nuclear factor kappa B (NF-κB). 2 In the present study, we focused on caspase recruitment domain family member 9 (CARD9), which functions as an essential signal adapter in the activation of NF-κB. 3, 4 CARD9 is known to work mainly in the innate immune system. 5 CARD9 seems to be strongly associated with inflammation, as it reportedly has strong correlation with inflammatory bowel disease. 6 Moreover, CARD9 has been reported to promote colon tumors in the adenomatous polyposis coli (APC min ) mouse model; surprisingly, this activity was specifically shown only in male mice. 7 And, in experimental colitis, CARD9 signaling promotes gut fungi-mediated inflammasome activation, which restricts colitis and colon cancer. 8 Furthermore, correlations between CARD9 and other types of cancer have been reported. For example, CARD9 overexpression is associated with the development or progression of gastric B-cell lymphoma. 9 In hepatocellular carcinoma, mRNA level of CARD9 is significantly higher and, therefore, CARD9 expression could be used as a diagnostic marker. 10 Moreover, in renal cell carcinoma, high CARD9 expression is associated with an increased risk of recurrence and shorter recurrence-free survival. 11 From these reports, it can be concluded that CARD9 plays an important role in NF-κB-mediated inflammatory response in cancers and exacerbates cancer by inducing inflammatory response. It has already been reported that ESCC with activated NF-κB has poor sensitivity to chemotherapy and that increased expression of NF-κB is associated with poor prognosis in patients with ESCC. 12 These reports suggest that CARD9 may influence ESCC by activating NF-κB. However, there is no report about the relationship between CARD9 and ESCC. Thus, we examined whether CARD9 can be used as a prognostic factor and further analyzed the function of CARD9 in ESCC.
| MATERIAL S AND ME THODS

| Patients and clinical specimens
We retrospectively investigated patients who underwent esophagectomy (with two-or three-field lymph node dissection, if necessary) at Chiba University Hospital between 2001 and 2011.
Patient medical records and survival status were retrospectively reviewed in January 2017.
Patients were eligible for this study if they: (i) were pathologically diagnosed with ESCC; (ii) were between 20 and 85 years of age; (iii) did not receive any preoperative treatment as chemotherapy; (iv) did not have any other types of cancer; and (v) achieved pathological R0 curative resection. The 11 patients who received postoperative adjuvant chemotherapy were included.
Data of 93 patients were examined after excluding patients who did not meet these criteria retrospectively. We obtained specimens from these patients and used them to evaluate CARD9 expression by immunohistochemistry. Informed consent was obtained from all patients for research purposes.
The tumor node metastasis (TNM) system (Union for International Cancer Control [UICC], 7th edition) was used to classify ESCC stages in these patients. 13 Patient characteristics (age, gender, and pathological evaluation) are shown in Table 1 .
| Esophageal squamous cell carcinoma cell culture and reagents
We used the human ESCC cell lines TE8 and T.Tn. TE8 cells were kindly provided by Dr T. Nishihira (Tohoku University, Sendai, Japan).
T.Tn cells were provided by the Japanese Cancer Research Resources
Bank.
Human ESCC cell lines were cultured in DMEM/nutrient mixture 
| Immunohistochemistry
Expression of CARD9 was assessed by immunohistochemistry using the peroxidase-antiperoxidase complex method. Anti-human CARD9 polyclonal antibody (1:100; ab115578; Abcam, Cambridge, UK) was used as the primary antibody, and anti-mouse/rabbit antibody (EnVision/HRP, anti-mouse/rabbit K5001; DAKO Japan, Tokyo, Japan) was used as the secondary antibody.
| Evaluation of CARD9 expression
Patients were divided into two groups. Staining intensity was judged as no staining (0 points), weak (1 point), moderate (2 points), or strong (3 points). Proportion of the stained cancer area was classified as <50% (1 point), 50%-80% (2 points), or >80% (3 points). Overall score was calculated by adding the staining intensity score to the proportion score. An overall score of two points or less was defined as low expression, and that of three points or more was defined as high expression. The diagnosis of CARD9 expression was confirmed by agreement with two pathologists. 
| Transfection of small interfering RNAs
| Quantitative reverse-transcription PCR and next-generation sequencing
Following the transfection of cells with siCARD9 or negative con- 
| Cell proliferation assay
Following transfection of cells with siCARD9 or negative control siRNA for 48 hours, the proliferation assay was carried out. The inhibitory influence of siCARD9 on cell proliferation was evaluated by measuring cell viability using Cell Counting Kit-8 (CCK-8;
Dojindo, Kumamoto, Japan). Cells were seeded in 96-well plates at 5 × 10 3 cells/well. After 72 hours, cell viability was determined using CCK-8. Absorbance was determined at 450 nm using a microplate reader.
| Cell migration assay
Cell migration assay was carried out using a micropore membrane filter with 8 μm pores as an insert (BD Biosciences, East Rutherford, NJ, USA). A total of 5 × 10 4 cells with DMEM/F-12 without FBS were seeded into the 24-well insert and, at the same time, siCARD9 or negative control siRNA was added. The lower chamber was filled with DMEM/F-12 containing 10% FBS as the attractant. After 24 hours, the cells on the upper side of the membrane were removed with cotton swabs, and the membranes were fixed and stained using Diff-Quik reagent (International Reagents, Hyogo, Japan). Cell migration was quantified by counting the number of migrated cells in a microscopic high-powered field per filter.
| Statistical analyses
Correlation between CARD9 expression levels and clinicopatho- 
| RE SULTS
| Relationship between CARD9 expression and clinicopathological features
Among the 93 cases studied, 33 (35.5%) had tumors with low and advanced stage (P = .001). Age and gender did not show statistically significant associations with high CARD9 expression ( Table 2) .
Postoperative adjuvant chemotherapy was carried out in four patients in the high CARD9 expression group and in seven patients in the low CARD9 expression group.
| Relationship between CARD9 expression and clinical prognosis
Analysis using Kaplan-Meier method and log-rank test showed that OS and DFS were significantly poor in the high CARD9 expression group (OS: P = .027, DFS: P = .005). Surprisingly, this tendency was shown only in males (OS, male: P = .014, female: P = .944) ( Figure 2 ).
Univariate analysis showed that advanced tumor depth, advanced stage, and high CARD9 expression were significant prognostic factors for OS. Multivariate analysis showed that the hazard ratio (HR) of high CARD9 expression was 2.039 (95% confidence interval
[CI] = 0.941-4.417, P = .071) ( Table 3 ).
For DFS, univariate analysis showed that advanced tumor depth, positive lymph node metastasis, advanced stage, and high CARD9 expression were significant prognostic factors.
Multivariate analysis showed that high CARD9 expression was an independent prognostic factor for DFS in these patients with ESCC (high CARD9 expression: HR = 2.538; 95% CI = 1.013-6.356, P = .047) ( Table 4 ). 
| Effect of CARD9 knockdown on proliferation and migration in ESCC cell lines
| Next-generation sequencing analysis
We comprehensively analyzed the effect of CARD9 on RNA expression in TE8 and T.Tn ESCC cell lines. Results are shown in Table 5 . 
TA B L E 2 Relationship between CARD9 expression and clinicopathological characteristics
| D ISCUSS I ON
The present study showed that CARD9, which plays an important role during the immune response in humans, influences malignancy in ESCC. Examination of the clinical specimens showed that CARD9 expression was scarce in normal tissue, but was occasionally higher in cancerous tissue. Expression of CARD9 in ESCC strongly correlated with cancer malignancy, with prognosis being significantly poor in the high-expression group. This makes CARD9 a significant prognostic factor for ESCC.
In addition, surprisingly, a remarkable difference was seen in OS between males of high-and low-CARD9 expression groups, whereas no significant difference was observed in females. However, the number of females was so small that this point is the limitation of the present study and a larger group in further study is necessary. It is important to elucidate the reason behind this gender difference.
Until now, only one other report has described the effect of CARD9 on carcinogenesis as gender specific. 7 However, the details remain unclear and further research is desired.
To elucidate the role of CARD9 in carcinogenesis in vitro, siRNA was used to knock down CARD9 in human ESCC cell lines. As a result, cell proliferation and migration were suppressed, which strongly correlated with tumor metastasis and invasion. Thus, CARD9 seems to correlate positively with cancer malignancy. Our data supported the hypothesis that CARD9 is a promising biomarker of ESCC prognosis and suggests that CARD9 could be a potential therapeutic target.
However, a molecular targeted antibody seems to be difficult to use for CARD9 because CARD9 is expressed intracellularly. Therefore, searching for molecules associated with CARD9 is very important for further examining its action and also for finding a better treatment method for ESCC. in ESCC cells inhibited cell proliferation, promoted apoptosis, and suppressed metastasis. 16 MEG3 also induces cell apoptosis through endoplasmic reticulum stress in ESCC. 17 It is widely accepted that cancer develops from chronic inflammatory fields and that microbial infection frequently causes chronic inflammation. 18 Additionally, CARD9 induces inflammation, which is associated with DNA methylation. 19 From these reports, it can be inferred that CARD9 may function through methylation-mediated silencing of MEG3 in ESCC.
In conclusion, the results of the present study suggest that by promoting chronic inflammation, CARD9 plays a major role in the development of ESCC. It is expected that CARD9 will become a promising prognostic biomarker for ESCC in the future, and it will be a potential target for ESCC treatment.
| S TATEMENT OF E THI C S
This study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the Graduate School of Medicine, Chiba University, Chiba, Japan.
Informed consent was obtained from all patients for research purposes.
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